MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting

• US 7,769,423 B2
• Filed: 12/29/2006
• Issued: 08/03/2010
• Est. Priority Date: 09/11/2002
• Status: Expired due to Fees

• Current Assignee: Duke University
• Original Assignee: Duke University
• Inventors: Ponce, Ana M., Dewhirst, Mark W., Viglianti, Benjamin L.
• Primary Examiner(s): Casler; Brian
• Assistant Examiner(s): CHAO, ELMER M
• Application Number:
  US11/648,148
• Publication Number:
  US 20070197904A1
• Time in Patent Office: 1,313 Days
• Field of Search: 600/407, 600/410, 600/411, 600/420, 424/9.321, 424/9.3, 424/9.36, 424/450
• US Class Current: 600/407
• CPC Class Codes: A61B 5/055 involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61K 41/0028 Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
• CPC Class Codes: A61K 49/1812 liposomes, polymersomes, e.g. immunoliposomes
• CPC Class Codes: A61K 51/1234 Liposomes
• CPC Class Codes: A61K 9/1271 Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers liposome as conjugate A61K47/6911
• CPC Class Codes: G01R 33/5601 involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent

Abstract

Methods and compositions useful for detecting an in vivo blood pool, monitoring the distribution of a compound of interest to a desired site in an organism by magnetic resonance imaging, monitoring the accumulation of a compound of interest at a desired site in vivo by magnetic resonance imaging, and monitoring the release of liposomal contents to an external stimulus at a desired site in vivo by magnetic resonance imaging are disclosed. Some compositions comprise envirosensitive or non-sensitive liposomes. Contrast agents, such as manganese-based compounds, are also disclosed.

Claims

1. A method of predicting efficacy of a treatment in a subject, the method comprising:

administering to a subject a liposome composition comprising;

(i) a contrast agent;

(ii) a compound of interest; and

(iii) a liposome encapsulating the contrast agent and the compound of interest;

monitoring accumulation of the compound of interest at a desired site in vivo by magnetic resonance imaging, wherein the monitoring comprises monitoring release of the contents of the liposome at the desired site by monitoring an increase in the presence of the contrast agent released from the liposome at the desired site as the contents of the liposome are being released at the desired site; and

predicting efficacy of treatment based on accumulation of the compound of interest at the desired site.

2. The method of claim 1, wherein the compound of interest is a chemotherapeutic agent.

3. The method of claim 1, wherein the liposome comprises a non-sensitive liposome.

4. The method of claim 3, wherein the non-sensitive liposome comprises DSPC/Cholesterol (55:

45, mol;

mol).

5. The method of claim 4, wherein the contrast agent comprises a element selected from the group consisting of Gd, Cu, Cr, Fe, Co, Er, Ni, Eu, Dy, Zn, Mg, Mo, Li, Ta, and Mn.

6. The method of claim 1, wherein the liposome comprises an envirosensitive liposome.

7. The method of claim 6, wherein the envirosensitive liposome is a liposome selected from the group consisting of a thermosensitive liposome, a pH-sensitive liposome, a chemosensitive liposome and a radiation-sensitive liposome.

8. The method of claim 7, wherein the thermosensitive liposome comprises a formulation selected from the group consisting of DPPC-PEG₂₀₀₀, DPPC-DSPE-PEG₂₀₀₀ (95:

5, mol;

mol), and DPPC-MSPC-DSPE-PEG₂₀₀₀ (90;

10;

4, mol;

mol).

9. The method of claim 6, wherein the contrast agent comprises a element selected from the group consisting of Gd, Cu, Cr, Fe, Co, Er, Ni, Eu, Dy, Zn, Mg, Mo, Li, Ta, and Mn.

10. The method of claim 6, further comprising exposing the envirosensitive liposome at the desired site to a non-physiological environmental condition.

11. The method of claim 10, wherein the environmental condition is selected from the group consisting of hyperthermia, electromagnetic radiation, a chemical agent and non-physiological pH.

12. The method of claim 1, wherein the desired site is selected from the group consisting of a tumor, an embolism, an injury site, an ischemia, and a tissue edema.

13. The method of claim 1, wherein the monitoring the accumulation of the compound of interest at the desired site by magnetic resonance imaging comprises making a pixel density determination.

14. The method of claim 1, wherein the predicting efficacy comprises predicting efficacy of treatment based on a location of accumulation at the desired site, a rate of accumulation at the desired site, or both location and rate of accumulation at the desired site.

48. The method of claim 1, further comprising monitoring accumulation of the compound of interest at a desired location at the desired site in vivo.

49. The method of claim 48, wherein the desired site is a tumor and the desired location comprises a vascular source of the tumor.

50. The method of claim 49, wherein the vascular source of the tumor is in a periphery of the tumor.

15. A method of enhancing efficacy of a treatment at a desired site in a subject, the method comprising:

administering to the subject a composition comprising;

(i) a contrast agent;

(ii) a compound of interest; and

(iii) a liposome encapsulating the contrast agent and the compound of interest; and

controlling the distribution of the compound of interest at a desired site by targeting the composition to a desired location within or proximate to the desired site in the subject, at a desired rate of accumulation at the desired site, or both a desired location and desired rate of accumulation at the desired site, to thereby enhance efficacy of treatment provided by the compound of interest, wherein controlling the distribution comprises monitoring accumulation of the compound of interest at a desired site, wherein monitoring comprises monitoring release of the contents of the liposome at the desired site by monitoring an increase in the presence of the contrast agent released from the liposome at the desired site as the contents of the liposome are being released at the desired site.

16. The method of claim 15, wherein the compound of interest is a chemotherapeutic agent.

17. The method of claim 15, wherein the liposome is a non-sensitive liposome.

18. The method of claim 17, wherein the non-sensitive liposome comprises DSPC/Cholesterol (55:

45, mol;

mol).

19. The method of claim 15, wherein the contrast agent comprises a element selected from the group consisting of Gd, Cu, Cr, Fe, Co, Er, Ni, Eu, Dy, Zn, Mg, Mo, Li, Ta, and Mn.

20. The method of claim 15, wherein the liposome is an envirosensitive liposome.

21. The method of claim 20, wherein the envirosensitive liposome is a liposome selected from the group consisting of a thermosensitive liposome, a pH-sensitive liposome, a chemosensitive liposome and a radiation-sensitive liposome.

22. The method of claim 21, wherein the thermosensitive liposome comprises a formulation selected from the group consisting of DPPC-PEG₂₀₀₀, DPPC-DSPE-PEG₂₀₀₀ (95:

5, mol;

mol), and DPPC-MSPC-DSPE-PEG₂₀₀₀ (90;

10;

4, mol;

mol)

23. The method of any one of claims 15, 17 and 20, wherein a non-physiological environmental condition is present at the desired site, and the composition is targeted to a desired location at the desired site in the subject, at a desired rate of accumulation at the desired site, or both a desired location and desired rate of accumulation at the desired site by the presence of the non-physiological environmental condition.

24. The method of claim 23, wherein the non-physiological environmental condition is selected from the group consisting of hyperthermia, electromagnetic radiation, a chemical agent and non-physiological pH.

25. The method of claim 24, wherein the hyperthermia is provided by a natural process or by a method selected from the group consisting of contacting a heated material with the desired site, applying RF energy to the desired site, applying ultrasonic energy to the desired site and applying a laser beam to the desired site.

26. The method of claim 23, wherein the desired site is exposed to a non-physiological environmental condition before, after, or both before and after administering the composition.

27. The method of claim 23, comprising administering the composition in one or more partial doses before, after, or both before and after the desired site is exposed to a non-physiological environmental condition.

28. The method of claim 15, wherein the desired site is selected from the group consisting of a tumor, an embolism, an injury site, an ischemia, and at a tissue edema.

29. The method of claim 15, further comprising monitoring accumulation of the compound of interest at the desired site in vivo by magnetic resonance imaging.

30. The method of claim 29, wherein the monitoring the accumulation of the compound of interest at the desired site by magnetic resonance imaging comprises making a pixel density determination.

31. The method of claim 15, further comprising predicting efficacy of treatment based on a location of accumulation at the desired site, a rate of accumulation at the desired site, or both the location and the rate of accumulation at the desired site.

51. The method of claim 15, wherein the desired site is a tumor and the desired location comprises a vascular source of the tumor.

52. The method of claim 51, wherein the vascular source of the tumor is in a periphery of the tumor.

32. A method of targeting delivery of a compound of interest at a desired site in vivo, the method comprising:

administering to a subject a composition comprising;

(i) a contrast agent;

(ii) a compound of interest; and

(iii) a liposome encapsulating the contrast agent and the compound of interest, wherein a non-physiological environmental condition is present at the desired site,

targeting the delivery of the compound of interest to a desired location within or proximate to the desired site in the subject, at a desired rate of accumulation at the desired site, or both a desired location and desired rate of accumulation at the desired site by the presence of the non-physiological environmental condition, and

monitoring accumulation of the compound of interest at a desired site, wherein monitoring comprises monitoring release of the contents of the liposome at the desired site by monitoring an increase in the presence of the contrast agent released from the liposome at the desired site as the contents of the liposome are being released at the desired site.

33. The method of claim 32, wherein the compound of interest is a chemotherapeutic agent.

34. The method of claim 32, wherein the liposome comprises a non-sensitive liposome.

35. The method of claim 34, wherein the non-sensitive liposome comprises DSPC/Cholesterol (55:

45, mol;

mol).

36. The method of claim 32, wherein the contrast agent comprises a element selected from the group consisting of Gd, Cu, Cr, Fe, Co, Er, Ni, Eu, Dy, Zn, Mg, Mo, Li, Ta, and Mn.

37. The method of claim 32, wherein the liposome comprises an envirosensitive liposome.

38. The method of claim 37, wherein the envirosensitive liposome is a liposome selected from the group consisting of a thermosensitive liposome, a pH-sensitive liposome, a chemosensitive liposome and a radiation-sensitive liposome.

39. The method of claim 38, wherein the thermosensitive liposome comprises a formulation selected from the group consisting of DPPC-PEG₂₀₀₀, DPPC-DSPE-PEG₂₀₀₀ (95:

5, mol;

mol), and DPPC-MSPC-DSPE-PEG₂₀₀₀ (90;

10;

4, mol;

mol).

40. The method of claim 32, wherein the non-physiological environmental condition is selected from the group consisting of hyperthermia, electromagnetic radiation, a chemical agent and non-physiological pH.

41. The method of claim 40, wherein the hyperthermia is provided by a natural process or a method selected from the group consisting of contacting a heated material with the desired site, applying RF energy to the desired site, applying ultrasonic energy to the desired site and applying a laser beam to the desired site.

42. The method of one of claims 32 and 40, wherein the desired site is exposed to a non-physiological environmental condition before, after, or both before and after administering the composition.

43. The method of one of claims 32 and 40, comprising administering the composition in one or more partial doses before, after, or both before and after the desired site is exposed to a non-physiological environmental condition.

44. The method of claim 32, wherein the desired site is selected from the group consisting of a tumor, an embolism, an injury site, an ischemia, and at a tissue edema.

45. The method of claim 32, further comprising monitoring accumulation of the compound of interest at the desired site in vivo by magnetic resonance imaging.

46. The method of claim 45, wherein the monitoring the accumulation of the compound of interest at the desired site by magnetic resonance imaging comprises making a pixel density determination.

47. The method of claim 32, further comprising predicting efficacy of treatment based on a location of accumulation at the desired site, a rate of accumulation at the desired site, or both location and rate of accumulation at the desired site.

53. The method of claim 32, wherein the desired site is a tumor and the desired location comprises a vascular source of the tumor.

54. The method of claim 53, wherein the vascular source of the tumor is in a periphery of the tumor.